92 related articles for article (PubMed ID: 22989364)
1. Is chemotherapy dose intensity adequate in breast cancer management in the Australian healthcare setting: a retrospective analysis.
Bae S; Yeung Y; Ng S; Craike M; Livingston PM; Chirgwin J
Asia Pac J Clin Oncol; 2014 Jun; 10(2):e54-62. PubMed ID: 22989364
[TBL] [Abstract][Full Text] [Related]
2. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.
Shayne M; Crawford J; Dale DC; Culakova E; Lyman GH;
Breast Cancer Res Treat; 2006 Dec; 100(3):255-62. PubMed ID: 16705366
[TBL] [Abstract][Full Text] [Related]
3. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
Lyman GH; Dale DC; Tomita D; Whittaker S; Crawford J
Breast Cancer Res Treat; 2013 Jun; 139(3):863-72. PubMed ID: 23771731
[TBL] [Abstract][Full Text] [Related]
4. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
[TBL] [Abstract][Full Text] [Related]
5. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.
Lyman GH; Dale DC; Crawford J
J Clin Oncol; 2003 Dec; 21(24):4524-31. PubMed ID: 14673039
[TBL] [Abstract][Full Text] [Related]
6. Relative dose intensity in early stage breast cancer chemotherapy: A retrospective analysis of incidence, risk factors and outcomes at a south-west Sydney cancer clinic.
Sandy J; Della-Fiorentina S
Asia Pac J Clin Oncol; 2013 Dec; 9(4):365-72. PubMed ID: 23937317
[TBL] [Abstract][Full Text] [Related]
7. Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice.
Weycker D; Barron R; Edelsberg J; Kartashov A; Lyman GH
Breast Cancer Res Treat; 2012 May; 133(1):301-10. PubMed ID: 22270932
[TBL] [Abstract][Full Text] [Related]
8. Maintaining Dose Intensity of Adjuvant Chemotherapy in Older Patients With Breast Cancer.
Ladwa R; Kalas T; Pathmanathan S; Woodward N; Wyld D; Sanmugarajah J
Clin Breast Cancer; 2018 Oct; 18(5):e1181-e1187. PubMed ID: 29778788
[TBL] [Abstract][Full Text] [Related]
9. Relative dose intensity as a proxy measure of quality and prognosis in adjuvant chemotherapy for breast cancer in daily clinical practice.
Schraa SJ; Frerichs KA; Agterof MJ; Hunting JCB; Los M; de Jong PC
Eur J Cancer; 2017 Jul; 79():152-157. PubMed ID: 28494406
[TBL] [Abstract][Full Text] [Related]
10. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
[TBL] [Abstract][Full Text] [Related]
11. Relative dose intensity--improving treatment and outcomes in early-stage breast cancer: a retrospective study.
Griffin DA; Penprase B; Klamerus JF
Oncol Nurs Forum; 2012 Nov; 39(6):E459-67. PubMed ID: 23107859
[TBL] [Abstract][Full Text] [Related]
12. Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy.
Shayne M; Culakova E; Wolff D; Poniewierski MS; Dale DC; Crawford J; Lyman GH
Cancer; 2009 Nov; 115(22):5319-28. PubMed ID: 19672945
[TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastim.
Balducci L; Mo M; Abella E; Saven A
Am J Clin Oncol; 2014 Dec; 37(6):603-10. PubMed ID: 25350463
[TBL] [Abstract][Full Text] [Related]
14. Association of relative dose intensity with BMI and pathologic complete response in patients treated with neoadjuvant chemotherapy for breast cancer.
Usiskin I; Li F; Irwin ML; Cartmel B; Sanft T
Breast Cancer Res Treat; 2021 Feb; 186(1):191-197. PubMed ID: 33125620
[TBL] [Abstract][Full Text] [Related]
15. Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy.
McCune JS; Sullivan SD; Blough DK; Clarke L; McDermott C; Malin J; Ramsey S
Pharmacotherapy; 2012 Jan; 32(1):7-19. PubMed ID: 22392824
[TBL] [Abstract][Full Text] [Related]
16. Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices.
Denduluri N; Patt DA; Wang Y; Bhor M; Li X; Favret AM; Morrow PK; Barron RL; Asmar L; Saravanan S; Li Y; Garcia J; Lyman GH
J Natl Compr Canc Netw; 2015 Nov; 13(11):1383-93. PubMed ID: 26553767
[TBL] [Abstract][Full Text] [Related]
17. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
Lyman GH; Dale DC; Friedberg J; Crawford J; Fisher RI
J Clin Oncol; 2004 Nov; 22(21):4302-11. PubMed ID: 15381684
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
19. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
[TBL] [Abstract][Full Text] [Related]
20. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
